- In March 2024, Bausch Health Companies Inc. and Alfasigma S.p.A. entered a licensing agreement to co-develop and commercialize Relistor (methylnaltrexone bromide) in selected European markets. The collaboration aims to expand the accessibility of PAMORAs across regions with growing opioid usage, particularly in oncology care. This strategic move underscores both companies’ commitment to advancing gastrointestinal safety in opioid-treated patients and addressing unmet needs in chronic care management
- In February 2024, Takeda Pharmaceutical Company Limited announced the initiation of a Phase III clinical trial evaluating a novel oral formulation of its investigational OIC treatment Naldemedine in patients with chronic non-cancer pain. The study highlights ongoing R&D investment in the segment and Takeda’s strategy to expand its portfolio in gastrointestinal supportive therapies through targeted, evidence-backed innovation
- In November 2023, AstraZeneca launched an expanded patient access program for Movantik (naloxegol) in North America to improve affordability for low-income patients suffering from OIC. The initiative focuses on widening access to effective prescription treatments for those on long-term opioid regimens, reinforcing AstraZeneca’s focus on patient-centric solutions and equitable healthcare delivery
- In October 2023, Mallinckrodt Pharmaceuticals announced the successful completion of a real-world evidence study on the use of Lubiprostone in opioid-treated palliative care patients. The findings demonstrated significant improvement in patient-reported quality of life and bowel movement frequency, further supporting Lubiprostone’s role in end-of-life and supportive care pathways
- In September 2023, Daiichi Sankyo Co., Ltd. partnered with several leading hospitals in Japan to pilot the use of AI-supported adherence tracking for OIC therapies, integrating digital health tools to improve compliance with prescribed OIC medications. The initiative reflects an emerging trend in combining pharmacotherapy with digital solutions to enhance outcomes, particularly in elderly and long-term care populations
